B-Cell Malignancies—Expert Guidance on BTK Inhibitors for Today’s Clinic
  • CME

In this on-demand Webcast of a CCO symposium at ASCO 2019, expert faculty review and discuss the latest data on using BTK inhibitors in the treatment of patients with B-cell malignancies.
Andrew D. Zelenetz, MD, PhD
Program Director
John C. Byrd, MD
Ian W. Flinn, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: July 11, 2019 Expiration: July 10, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate differences among agents targeting BTK in terms of molecular characteristics, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Consider existing and emerging clinical research data evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) in the formulation of therapeutic recommendations for patients with MCL, CLL, and other B-cell malignancies
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support quality of life and continuation of treatment
  • Explain to patients the importance of and provide strategies for optimal adherence to prescribed BTK inhibitors
  • Assess ongoing clinical trials evaluating currently available and emerging BTK inhibitors (and BTK-based combinations) to aid clinical trial enrollment and predict new options in the clinic

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Adaptive Biotech, Amgen, AstraZeneca, Celgene, Genentech/Roche, Gilead Sciences, Janssen, MorphoSys, Novartis, Pharmacyclics, and Verastem; funds for research support from BeiGene, Gilead Sciences, MEI Pharm, and Roche; and other funding/support from BeiGene and Juno.

Faculty

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Distinguished University Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Senior Advisor for Cancer Experimental Therapeutics
Department of Medicine
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, Ohio

John C. Byrd, MD, has disclosed that he has received funds for research support from Acerta, Genentech, Janssen, and Pharmacyclics.
Ian W. Flinn, MD, PhD

Director, Lymphoma Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Ian W. Flinn, MD, PhD, has disclosed that his organization has received consulting fees from AbbVie, Seattle Genetics, TG Therapeutics, and Verastem and funds for research support from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse has ownership interest in and receives salary from AstraZeneca.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with MCL, CLL, and other B-cell malignancies.

Goal

The goal of this activity is to improve participants’ competence in using BTK inhibitors to improve treatment outcomes for patients with B-cell malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 11, 2019, through July 10, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

This downloadable resource includes a proposed 2019 treatment algorithm for myeloma and a list of key ongoing or enrolling clinical trials for patients with myeloma

Ajai Chari, MD Released: August 22, 2019

John M. Burke, MD, and Shaji Kumar, MD, discuss practice-changing presentations in lymphomas, CLL, and multiple myeloma from ASCO 2019.

John M. Burke, MD Shaji Kumar, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 16, 2019 Expiration: August 15, 2020

Noopur Raje, MD: Clinical impact of latest data for idecabtagene vicleucel (bb2121) and other CAR T-cells in relapsed/refractory multiple myeloma.

Noopur Raje, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 16, 2019 Expiration: August 15, 2020

Expert insights from Alessandra Tedeschi, MD, on new data for B-cell malignancy management reported at the 2019 EHA and ICML meetings

person default Alessandra Tedeschi, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 13, 2019 Expiration: August 12, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?